{"schema_version":"1.0","type":"article","title":"Who Could Be Big Pharma's Next Major Biotech Acquisition?","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.md","lang":"en","date":"2026-08-23","publish_at":"2026-08-23T08:00:00+08:00","updated_at":"2026-08-23","category":"商業分析系列","topic":"商業分析系列","tags":["biotech M&A","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","Pharmosa Biopharm","Belite Bio","BD licensing"],"summary":"Biopharma acquisition capital in 2026 is clustering around a narrow window: human risk has started to fall, but strategic value is not yet fully priced. Alkermes, Dyne, First Tracks, Legend and Sail illustrate five ways a biotech can enter that window, while Taiwan's Pharmosa Biopharm and Belite Bio show how late-stage assets can speak the same global language.","key_points":[],"facts":[],"sections":["01 | Recent deals have rewritten the acquisition standard","02 | As orexin heats up, Alkermes occupies a more sensitive position","03 | After Avidity, Dyne is the most visible independent muscle-delivery platform","04 | Once CD122 became transactible, First Tracks became harder to ignore","05 | Legend Biotech is now worth more than Carvykti alone","06 | J&J has already secured an option on Sail","07 | Which Taiwan companies speak the new acquisition language?","Conclusion | The next major deal may happen where risk has just started to fall","References","Disclaimer"],"references":[{"title":"[Novartis: Successful completion of the Avidity Biosciences acquisition]","source":"","date":"","url":"https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy"},{"title":"[Gilead Sciences: Completion of the Arcellx acquisition]","source":"","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Eli Lilly: Agreement to acquire Centessa Pharmaceuticals]","source":"","date":"","url":"https://investor.lilly.com/node/54066"},{"title":"[Eli Lilly: Agreement to acquire AtaiBeckley]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant"},{"title":"[argenx: Agreement to acquire Forte Biosciences and add FB102]","source":"","date":"","url":"https://argenx.com/news/2026/press-release-3333257.html"},{"title":"[Alkermes: Initiation of the Phase 3 Brilliance studies]","source":"","date":"","url":"https://investor.alkermes.com/node/23196/pdf"},{"title":"[Alkermes: Detailed positive results from the Phase 2 Vibrance-2 study]","source":"","date":"","url":"https://investor.alkermes.com/news-releases/news-release-details/alkermes-presents-detailed-positive-results-vibrance-2-phase-2/"},{"title":"[Dyne Therapeutics: FDA accepts the z-rostudirsen BLA and grants Priority Review]","source":"","date":"","url":"https://www.dyne-tx.com/fda-accepts-bla-for-z-rostudirsen/"},{"title":"[First Tracks Biotherapeutics: Second-quarter 2026 pipeline update]","source":"","date":"","url":"https://ir.firsttracksbio.com/news-releases/news-release-details/first-tracks-biotherapeutics-announces-second-quarter-2026"},{"title":"[First Tracks Biotherapeutics: ANB033 program overview]","source":"","date":"","url":"https://www.firsttracksbio.com/our-pipeline/anb033/overview/"},{"title":"[Legend Biotech: First-quarter 2026 results and Carvykti sales]","source":"","date":"","url":"https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-reports-first-quarter-2026-results-and-recent/"},{"title":"[Legend Biotech: Preliminary Phase 1 proof of concept for LB2501]","source":"","date":"","url":"https://investors.legendbiotech.com/news-releases/news-release-details/legend-biotech-establishes-clinical-proof-concept-lb2501/"},{"title":"[Johnson & Johnson: Strategic collaboration with Sail Biomedicines]","source":"","date":"","url":"https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-Announces-Collaboration-with-Sail-Biomedicines-to-Advance-in-vivo-CAR-T-Programs-and-Transform-Autoimmune-Disease-Through-Immune-Reset/default.aspx"},{"title":"[ClinicalTrials.gov: Re-Spire Phase 3 study of L606 in PH-ILD, NCT07285655]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07285655"},{"title":"[Belite Bio: Positive topline results from the Phase 3 DRAGON trial]","source":"","date":"","url":"https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite"},{"title":"[Belite Bio: Completion of the rolling NDA submission for tinlarebant]","source":"","date":"","url":"https://investors.belitebio.com/news-releases/news-release-details/belite-bio-completes-rolling-submission-new-drug-application-us"},{"title":"Verification cutoff: August 23, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | The new acquisition standard combines human proof of concept, platform expansion, strategic fit and value that has not yet been fully priced","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-01.png"},{"alt":"Figure 2 | Alkermes has advanced alixorexton into global Phase 3 while using orexin biology to explore a broader neuroscience platform","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-02.png"},{"alt":"Figure 3 | Following the Avidity and Forte transactions, Dyne's muscle-delivery platform and First Tracks' CD122 program are the two routes most exposed to repricing","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-03.png"},{"alt":"Figure 4 | Legend, Sail, Pharmosa and Lin BioScience illustrate four acquisition languages: commercial revenue, next-generation platforms, option-based positioning and late-stage specialist assets","url":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-23）。Who Could Be Big Pharma's Next Major Biotech Acquisition?。https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-23-big-pharma-biotech-ma-next-targets-2026.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}